Pyxis Oncology, Inc. 8K

Pyxis Oncology appointed Thomas Civik as permanent CEO and Chairman, with John Flavin becoming Lead Independent Director, in a leadership transition tied to advancement of its MICVO clinical programs.

Pyxis Oncology, Inc. announced that its Board of Directors has appointed Thomas Civik, previously Interim Chief Executive Officer and a director since 2021, as permanent Chief Executive Officer and Chairman of the Board effective September 4, 2026, while co-founder and founding Chairman John Flavin will transition to the role of Lead Independent Director and remain on the Board, as the company continues to advance its lead asset MICVO through key Phase 1 and Phase 1/2 clinical milestones in recurrent/metastatic head and neck squamous cell carcinoma with additional data updates expected in fall and fourth quarter 2026.

Filing Facts

CIK

1782223

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-384386

Alert Tier

7